Thus, ASNS expression is a predictive biomarker in several human cancer types (14, 15) whereas asparaginases, that degrade extracellular asparagine, are a key chemotherapeutic drug for the treatment of leukemia and lymphomas that lack ASNS expression (13). Here, ASNS is linked to lymphoma.